A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
Latest Information Update: 08 Nov 2022
At a glance
- Drugs Gedatolisib (Primary) ; Cisplatin; Dacomitinib; Docetaxel
- Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 05 Nov 2022 Results published in the British Journal of Cancer
- 10 Aug 2020 Status changed from recruiting to completed.
- 16 Oct 2019 Planned End Date changed from 18 Oct 2019 to 10 Jan 2020.